The agenda includes:
Preparation of positions on the evaluation of drugs:
- Saphnelo (anifrolumab) under the drug programme “Treatment of patients with active systemic lupus erythematosus (SLE) (ICD 10: M32)”,
- Glypvilo (vildagliptin) for the indication: treatment of type 2 diabetes mellitus,
- Keytruda (pembrolizumab) under the drug programme “Follow-up treatment of patients with renal cell carcinoma (ICD-10 C64)”.
Preparation of a position on the legitimacy of granting reimbursement approvals for the drug Renastart for the indication: chronic renal failure in paediatric patients over 2 years of age.
Preparation of opinions on draft health policy programmes of local government units:
- “Programme of early detection of colorectal cancer among residents of the Municipality of Pszczyna for 2023-2027”,
- “Type 2 diabetes prevention programme for the residents of Pszczyna aged 45-65 for 2023-2027”.